Investigating outcomes after salvage surgery for recurrent head and neck cancer
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
This study tests how well salvage surgery works for people with recurrent head and neck cancer and looks at how genetics and past treatments might affect their recovery and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 9 sites (Derby and 8 other locations) |
| Trial ID | NCT05808920 on ClinicalTrials.gov |
What this trial studies
The RESCUE study is a multicentre cohort investigation that looks at both retrospective and prospective data to evaluate survival and functional outcomes in patients who undergo salvage surgery for recurrent, residual, or new primary head and neck squamous cell carcinoma (SCC). It also includes an exploratory molecular analysis to understand the relationship between cancer genomics, prior radiotherapy, and recurrence. The study aims to provide insights into the quality of life and genetic factors influencing treatment outcomes in this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a history of head and neck SCC treated with radiotherapy, who are experiencing local or regional recurrence.
Not a fit: Patients with nasopharyngeal or cutaneous SCC, distant metastasis, or inoperable tumors will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies and outcomes for patients with recurrent head and neck cancer.
How similar studies have performed: Other studies have explored similar salvage surgery approaches, but the specific combination of molecular analysis and outcomes in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged over 18 2. Previous H\&N SCC treated with radiotherapy with or without chemotherapy 3. Local or regionally recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx 4. Ability to give informed consent for biological sample collection (molecular analysis study only) Exclusion Criteria: 1. Nasopharyngeal and cutaneous SCC of the H\&N 2. Thyroid, salivary gland, and non-squamous cell H\&N cancers 3. Presence of distant metastasis (M1) or surgically inoperable T4b tumours
Where this trial is running
Derby and 8 other locations
- University Hospitals Derby and Burton — Derby, United Kingdom (Recruiting)
- NHS Lothian — Edinburgh, United Kingdom (Recruiting)
- Western General, Greater Glasgow and Clyde — Glasgow, United Kingdom (Recruiting)
- Aintree Hospital — Liverpool, United Kingdom (Recruiting)
- Head and Neck Unit, Royal Marsden Hospital — London, United Kingdom (Recruiting)
- Northwick Park — London, United Kingdom (Recruiting)
- Oxford University Hospital NHS Foundation Trust — Oxford, United Kingdom (Recruiting)
- Poole Hospital, University Hospitals Dorset — Poole, United Kingdom (Recruiting)
- South Tyneside and Sunderland NHS Foundation Trust — Sunderland, United Kingdom (Completed)
Study contacts
- Principal investigator: Vinidh Paleri — Royal Marsden Hospital NHS Foundation Trust
- Study coordinator: Andrew Williamson
- Email: andrew.williamson2@rmh.nhs.uk
- Phone: 02073528171
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.